A Systematic Review of Metformin Therapy and Renal Outcomes in Type 2 Diabetes Mellitus (
DOI:
https://doi.org/10.12970/2310-9971.2016.04.01.1Keywords:
Metformin, Type 2 diabetes, nephropathy, systematic review.Abstract
Background: Nephropathy is an important sequelae of diabetes. Current clinical study of the potential nephroprotective effects of metformin in diabetes is small and outcomes of individual studies insufficient to arrive at a firm conclusion. The objective of this systematic review is to evaluate the relationship between metformin treatment and specific renal outcomes in patients with Type 2 Diabetes Mellitus (T2DM). Methods: Two authors independently performed comprehensive searches in relevant health care databases using pre-determined search terms. Included articles described metformin treatment compared to control group(s) whereby baseline and follow-up parameters of relevant renal outcome were adequately described. Study characteristics, outcomes, and methodological quality were extracted according to standard protocols. Results: Initial search yielded 1,147 articles of which 7(6 prospective and 1 retrospective) studies meeting inclusion criteria were included in the overall analysis totaling 62,993subjects exposed to metformin. Comparators included thiazolidinediones (TZDs), sulfonylureas (SUs) and insulin in studies spanning 12 weeks to 4 years. When change from baseline values is compared, metformin demonstrated a more pronounced increase in albumin to creatinine ratio (ACR) than SUs (mean difference [MD] 14.8 mg/g [-4.2 to 25]), while TZDs were consistently associated with improvements. No significant difference in glomerular filtration rate (eGFR) was observed between metformin and TZD (MD 0.22 mL/min [-0.24 to 0.68]), while data between metformin and SU was conflicting. Conclusions: The potential nephroprotective effects of metformin in diabetes patients with or without evidence of pre-existing proteinuria are not supported by our findings. Further long-term prospective study among larger populations is needed.References
[1] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65. http://dx.doi.org/10.1016/S0140-6736(98)07037-8
[2] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89. http://dx.doi.org/10.1056/NEJMoa0806470
[3] International Diabetes Federation. Global guideline for Type 2 Diabetes [article online], 2012. Available from http: //www.idf.org/publications/global-guideline-type-2-diabetes. Accessed 4 July 2015.
[4] Bristol-Myers Squibb. Glucophage (metformin hydrochloride) tablets package insert. Princeton, NJ. 2010.
[5] Marquess JG. Managing special populations among patients with type 2 diabetes mellitus. Pharmacotherapy 2011; 31(12 Part 2): 65S-72S. http://dx.doi.org/10.1592/phco.31.12.65S
[6] Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure. Circ Heart Fail 2013; 6: 395-402. http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000162
[7] Lipska K, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-7. http://dx.doi.org/10.2337/dc10-2361
[8] Holstein A, Nahrwold D, Hinze S, Egberts EH. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999; 16: 692-6. http://dx.doi.org/10.1046/j.1464-5491.1999.00115.x
[9] Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 2001; 18: 483-8. http://dx.doi.org/10.1046/j.1464-5491.2001.00509.x
[10] Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Therapm 2009; 31: 2608-17. http://dx.doi.org/10.1016/j.clinthera.2009.10.020
[11] Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2(4). http://dx.doi.org/10.1136/bmjopen-2012-001076
[12] Roussel R, Travert F, Pasquet B, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-9. http://dx.doi.org/10.1001/archinternmed.2010.409
[13] Satriano J, Sharma K, Blantz RC, Deng A. Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease.. Am J Physiol Renal Physiol 2013; 305: F727-F33. http://dx.doi.org/10.1152/ajprenal.00293.2013
[14] Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA. Metformin attenuates streptozotocininduced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 2011; 192: 233-42. http://dx.doi.org/10.1016/j.cbi.2011.03.014
[15] Kim J, Shon E, Kim CS, Kim JS. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res 2012 2012(210821). http://dx.doi.org/10.1155/2012/210821
[16] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic re- views and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. http://dx.doi.org/10.1136/bmj.b2700
[17] Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. Grading the strength of a body of evidence when comparing medical interventions - Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol 2010; 63: 513-23. http://dx.doi.org/10.1016/j.jclinepi.2009.03.009
[18] Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care1998; 21: 2135-9. http://dx.doi.org/10.2337/diacare.21.12.2135
[19] Amador-Licona N, Guizar-Mendoza JM, Vargas E, SanchezCamargo G, Zamora-Mata L. The short-term effect of a switch from glybenclamide to metformin on blood pressure and microalbuminuria in patients with Type 2 Diabetes Mellitus. Arch Med Res 2000; 31: 571-5. http://dx.doi.org/10.1016/S0188-4409(00)00241-1
[20] Hanefield M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel EH on behalf of the QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care 2004; 27: 141-7. http://dx.doi.org/10.2337/diacare.27.1.141
[21] Hanefeld M, Pfutzner A, Forst T, Kleine I, Fuchs W. Doubleblind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 2011; 10: 65. http://dx.doi.org/10.1186/1475-2840-10-65
[22] Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011; 6: 1032-40. http://dx.doi.org/10.2215/CJN.09291010
[23] Morikawa A, Ishizeki K, Iwashima Y, Yokoyama H, Muto E, Oshima E, et al. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. Clin Exp Nephrol 2011; 15: 848-53. http://dx.doi.org/10.1007/s10157-011-0512-3
[24] Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012; 81: 698-706. http://dx.doi.org/10.1038/ki.2011.444
[25] Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int 2011; 79(Supplement 120): S28-S32. http://dx.doi.org/10.1038/ki.2010.513
[26] Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2014; 7: 13-24.
[27] Association AD. Standards of Medical Care in Diabetes - 2015. Diabetes Care 2015; 38(Supplement 1).
[28] Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-9. http://dx.doi.org/10.2337/dc14-2441
[29] McCormack J, Johns K, Tidesley H. Metformin's contraindications should be contraindicated. CMAJ 2005; 173: 502-4. http://dx.doi.org/10.1503/cmaj.045292
[30] Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163: 2594-53. http://dx.doi.org/10.1001/archinte.163.21.2594
[31] Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: A patient-centered comparative effectiveness study. JAMA Internal Medicine 2014; 174: 1955-62. http://dx.doi.org/10.1001/jamainternmed.2014.5294
[32] Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic management of type 2 diabetes. Can J Diabetes 2013; 37(Supplement 1): S61-S8. http://dx.doi.org/10.1016/j.jcjd.2013.01.021
[33] Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab2013; 98: 668-77. http://dx.doi.org/10.1210/jc.2012-3042
[34] Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, Albayrak G, et al. The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 2013; 182: 176-84. http://dx.doi.org/10.1016/j.jss.2012.08.020
[35] Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006; 21: 2399-405. http://dx.doi.org/10.1093/ndt/gfl212
[36] Pistrosch F, Passauer K, Herbrig K, Schwanebeck U, Gross P, Bornstein SF. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 2012; 44: 914-8. http://dx.doi.org/10.1055/s-0032-1314836
[37] Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 2010; 55: 835-47. http://dx.doi.org/10.1053/j.ajkd.2009.11.013
[38] Kidney Disease Improving Global Outcomes (KDIGO) 2012. Clinical practice guideline for the Evaluation and managmeent of chronic kidney disease. Kidney Int 2013; 3(1): Supplement 1.
[39] Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-9. http://dx.doi.org/10.1001/jama.2010.39
[40] Hoefield RA, Karla PA, Baker PG, Souda I, Diggle J, Gibson MJ, et al. The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant 2011; 26: 887-92. http://dx.doi.org/10.1093/ndt/gfq526
[41] Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Asses 2005; 9(30).
[42] Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M et al. for the Renal Insufficiency and Cardiovascular Events Study Group. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment intype 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian multicenter study. JAGS 2013; 61: 2353-61. http://dx.doi.org/10.1111/jgs.12381
[43] UK Prospective Diabetes Study (UKPDS) Group. Risk factors for renal dysfunction in Type 2 diabetes. (UKPDS 74). Diabetes 2006; 55: 1832-1839. http://dx.doi.org/10.2337/db05-1620
[44] UK Prospective Diabetes Study (UKPDS) Group. Development and progression of nephropathy in Type 2 diabetes: The United Kingdom Prospective Diabetes Study(UKPDS 64). Kidney Int 2003; 63: 225-232. http://dx.doi.org/10.1046/j.1523-1755.2003.00712.x
[45] Hung SC, Chang YK, Lius S, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational cohort study. Lancet Diabetes Endocrinol 2015; 3: 605-614. http://dx.doi.org/10.1016/S2213-8587(15)00123-0
